|
WO2013041239A1
|
|
Pkm zeta bindin peptides, peptide derivatives and conjugates, and uses thereof
|
|
WO2013041238A1
|
|
Use of kibra peptides, hdac inhibitor or proteasome inhibitor for improving anxiety disorders
|
|
EP2573108A1
|
|
Methods for identifying compounds capable of inhibiting degradation of PKM zeta
|
|
EP2398493A1
|
|
Use of g-csf for the extension of the therapeutic time-window of thrombolytic stroke therapy
|
|
EP2354789A1
|
|
Method for the identification of memory modulating compounds by assessing KIBRA expression
|
|
EP2330418A1
|
|
Methods of quantitative determination of neurogenesis in vivo
|
|
EP2332917A1
|
|
Compounds for PIM kinase inhibition and for treating malignancy
|
|
EP2251010A1
|
|
Use of thiabendazole and derivatives thereof for the therapy of neurological conditions
|
|
EP2036571A1
|
|
Use of G-CSF for treating strokes
|
|
EP2030617A1
|
|
Use of tranilast and derivatives thereof for the therapy of neurological conditions
|
|
EP2011495A1
|
|
Use of piperine and derivatives thereof for the therapy of neurological conditions
|
|
US2005142102A1
|
|
Methods of treating neurological conditions with hematopoietic growth factors
|
|
US2004141946A1
|
|
Methods of treating neurological conditions with hematopoietic growth factors
|
|
US7361681B2
|
|
Method of treating amytrophic lateral sclerosis using melatonin
|
